检索结果-南通市图书馆

CLINICAL APPLICATION OF BOTULINUM TOXIN TYPE B IN MOVEMENT DISORDERS AND AUTONOMIC SYMPTOMS

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Sciences Journal 2005年第1期20卷 44-47,页

作者： Xin-huaWan KevinDatVuong JosephJankovic DepartmentofNeurology PekingUnionMedicalCollegeHospitalChineseAcademyofMedicalSciences＆PekingUnionMedicalCollegeBeijing100730 Parkinson＇sDiseaseCenterandMovementDisordersClinic BaylorCollegeofMedicineHoustonTexasUSA77030

Objective To evaluate efficacy and safety of botulinum toxin type B (BTX-B) in treatment of movement disorders including blepharospasm, oromandibular dystonia, hemifacial spasm, tremor, tics, and hypersecretory disorders such as sia-lorrhea and hyperhidrosis. Methods A retrospective study of BTX-B injections in treatment of 58 patients with various neurological disorders was performed. The mean follow-up time was 0.9 ± 0.8 years. Results of the first and last treatment of patients with at least 3 injection sessions were compared. Results The response of 58 patients to a total of 157 BTX-B treatment sessions was analyzed. Of the 157 treatment sessions, 120 sessions (76.4%) resulted in moderate or marked improvement while 17 sessions (10.8%) had no response. The clinical benefits after BTX-B treatment lasted an average of 14 weeks. Of the 41 patients with at least 3 injection ses-sions (mean 10 ± 8.6), most patients needed increased dosage upon the last session compared to the first session. Nineteen patients (32.8%) with 27 sessions (17.2%) reported adverse effects with BTX-B treatment. Conclusions Though most patients require increased dosage to maintain effective response after repeated injections, BTX-B is an effective and safe treatment drug for a variety of movement disorders, as well as drooling and hyperhidrosis.

关键词： botulinum toxin type B movement disorders sialorrhea

Treatment with botulinum toxin: An update

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Neurology 2013年第3期3卷 29-41页

作者： Esteban Pe?a Department of Neurology Hospital Sanitas La Moraleja 28050 Madrid Spain

Botulinum neurotoxin(Bo NT) is a potent toxin produced by the anaerobic bacterium clostridium botulinum. It causes flaccid, long-lasting, local and reversible paralysis. In addition, Bo NT inhibits the secretion of the exocrine glands and could have properties in the control of pain. Thus, Bo NT is useful in the treatment of many neuromuscular conditions where an increase of muscle tone is associated with the pathogenic mechanism. Furthermore, Bo NT is recommended in the treatment of some hypersecretion disorders of the exocrine gland and could play a role in the treatment of migraine and other chronic pain conditions. In the Bo NT therapy adverse effects are usually mild and reversible. However, repeated injections of Bo NT can lead to the development of neutralizing antibodies that can subsequently inhibit the biological activity of the toxin. In this sense, many factors can influence the immunogenicity of the Bo NT, such as product-related factors, the dose of Bo NT used, the frequency of injection and the previous exposure to the toxin. In this review, we are going to discuss the current clinical applications of Bo NT with a special focus on evidence, doses, injection technique and adverse effects for those applications more frequently used in neurology, namely spasticity, blepharospasm, hemifacial spasm, cervical dystonia and other focal dystonias, as well as chronic migraine, tremor, sialorrhea, facial palsy, neurogenic bladder and many other neurological condition.

关键词： Botulinum toxin Dystonia Spasticity Headache Migraine Pain Tremor sialorrhea Facial palsy Neurogenic bladder

Clinical and Laryngotracheoscopic Evaluation of Children with Cerebral Palsy Using Intraparotid Injections of Botulinum Toxin Type A for Drooling Control

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Surgical Science 2018年第1期9卷 44-51页

作者： Juliana Benthien Cavichiolo Sérgio Bernardo Tenório Elise Zimmermann Fabiano Bleggi Gavazzoni Rodrigo Guimarã es Pereira Elmar Fugmann Department of Clinical Surgery Hospital Pequeno Príncipe Curitiba Brasil Department of Anesthesiology Hospital de Clínicas da UFPR and Hospital Pequeno Príncipe Curitiba Brasil Department of ENT Surgery Hospital Pequeno Príncipe Curitiba Brasil Department of Otorhinolaryngology Hospital Pequeno Príncipe Curitiba Brasil Department of Clinical Surgery Hospital de Clínicas da UFPR Curitiba Brasil

Introduction: Medical literature shows consistent data on the use of botulinum toxin for the treatment of drooling, especially in patients with neurological disorder. However, any trial evaluated the reduction of sialorrhea through laryngotracheoscopy. Objective: To evaluate the reduction of salivation and aspiration in children with cerebral palsy submitted to intraparotid injection of botulinum toxin. Methods: A prospective cohort study including 31 pediatric patients with cerebral palsy who complained of sialorrhea and were submitted to an intraparotid injection of botulinum toxin type A. It was analysed the reduction of the number of bibs and the amount of saliva in the larynx and trachea through a laryngotracheoscopic examination. Results: There was a reduction in the number of bibs from 7.35 to 4 after application of BoNT/A, with p-value Conclusion: Application of botulinum toxin type A is a good method for temporary control of salivation in children with neurological disorders.

关键词： Botulinum Toxin sialorrhea Laryngotracheoscopy

Pure Salivatory Seizures Secondary to a Subtle Malformation of the Right Parietal Cortex

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neuroscience & Medicine 2016年第1期7卷 10-14页

作者： Fábio A. Nascimento Danah Aljaafari Murilo de Souza Meneses Samanta Fabrício Blattes da Rocha Cristiane Simão Pedro A. Kowacs Division of Neurology Toronto Western Hospital University of Toronto Toronto Canada Deparment of Neurology King Fahad Hospital of University University of Dammam Dammam Saudi Arabia Neurological Institute of Curitiba (INC) Curitiba Brazil

Background: Salivatory seizures are a singularly rare condition, which can occur both in idiopathic and symptomatic epilepsies. Objectives: To describe and discuss the case of an adolescent patient with sleep-triggered “pure” salivatory seizures associated with a subtle cortical malformation of the right parietal cortex. Case report: Herein, we report a 17-year-old female who started to present salivatory paroxysms, which occasionally secondarily generalized, shortly after falling asleep, at the age of eight years. Video-electroencephalographic monitoring with scalp electrodes failed to show any epileptiform activity during the several recorded clinical events. Brain MRI and curvilinear reconstruction revealed, in the three orthogonal planes, a subtle cortical thickening, limited to a single gyrus in the right parietal cortex, suggestive of a focal cortical malformation. After antiepileptic drug therapy was optimized, the patient became seizure-free. Conclusion: An epilepsy diagnosis should be pursued in patients presenting isolated, paroxysmal hypersalivation, despite possible negative scalp EEG studies.

关键词： Salivatory Seizures Malformation of Cortical Development Hypersalivation sialorrhea